Zero Candida Technologies: Trading Milestone on OTCQB Market
Zero Candida Technologies Begins OTCQB Trading
Zero Candida Technologies, Inc. is making waves in the investment community as its common shares officially commence trading on the OTCQB Venture Market under the ticker symbol ZCTFF. This move marks a significant step for the FemTech medical device company that focuses on revolutionary solutions for women's health. Additionally, the company will maintain its listings on both the TSX Venture Exchange and the Frankfurt Stock Exchange.
Eli Ben Haroosh Shares Excitement for Growth
The Founder and CEO, Eli Ben Haroosh, expressed enthusiasm regarding this milestone in a recent comment. He highlighted that this achievement reflects their potential for long-term growth. The company aims to broaden its market presence, establish strategic partnerships, and expand its investor base. The CEO emphasized the use of AI-driven technology as a means to unlock substantial value, especially in light of recent patent advancements and increasing market demand for Vaginal Candidiasis treatment.
Importance of OTCQB for Company Growth
The OTCQB is recognized as a premier market for early-stage U.S. and international companies. Operated by the OTC Markets Group and acknowledged by the U.S. Securities and Exchange Commission (SEC), it serves as a platform for companies to foster transparency and shareholder value. For Zero Candida, this listing could enhance its visibility and support its commitment to meeting compliance and financial reporting requirements.
Innovative Solutions in Women's Health
Zero Candida is proactive in developing innovative health solutions tailored for women. The cornerstone of their technology is a unique tampon-like device designed to treat Candida fungus effectively through AI and therapeutic blue light usage. This device has showcased a remarkable 99.999% success rate in point-of-care settings. With Vulvo-Vaginal Candidiasis (VVC) affecting a considerable percentage of women, the potential of this device could provide much-needed relief amid rising resistance to conventional treatments.
Future Outlook and Clinical Trials
As they prepare for an upcoming clinical trial, Zero Candida remains focused on finalizing their device for human use after successfully completing preliminary safety trials in large animals. The company is also securing collaborations with leading hospitals and expanding its patent portfolio globally, including applications in the U.S., Brazil, and Europe, while fully patenting in South Africa.
Market Potential and Commitment to Patients
With the market for VVC treatment projected to surpass USD $2 billion in the next five years, Zero Candida's approach seeks to integrate advanced medicine with technology-based diagnostics. The ultimate goal is to improve healthcare access for underrepresented populations and modernize gynecological practices, ensuring women receive the best possible care.
Company Contacts
For further inquiries, Zero Candida provides direct contacts for their team. Victoria Gamble is available at victoria@zero-candida.com, and Eli Ben Haroosh can be reached at info@zero-candida.com. Their phone number is (647) 874 3767.
Frequently Asked Questions
What is Zero Candida Technologies?
Zero Candida Technologies, Inc. is a FemTech company specializing in innovative medical solutions tailored to women's health.
What is the significance of the OTCQB listing?
The OTCQB listing enhances visibility for investors and supports the company's growth ambitions by providing a platform for increased trading activity.
What are Zero Candida's primary health solutions?
They are developing an innovative device that addresses Vulvo-Vaginal Candidiasis using AI and therapeutic blue light technology.
How effective is the device developed by Zero Candida?
The device has a proven success rate of 99.999% in clinical trials at point-of-care settings.
How can I reach Zero Candida for more information?
You can contact Victoria Gamble at victoria@zero-candida.com or Eli Ben Haroosh at info@zero-candida.com.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.